drugset / Trial / NCT04629651

Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms

NCT04629651

Phase 1/2 Withdrawn Case Comprehensive Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of captopril and evaluate the effectiveness captopril as measured by changes in the grade of bone marrow scar tissue. The change in spleen size by ultrasound will also be measured.

Timeline

Start
2024-04
Primary completion
2024-10
Completion
2024-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Captopril Small molecule 150 mg Oral

Indications